🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06580860
Recruiting Observational

Psychiatric Multi-omics and Neuroimaging Project

NCT06580860 · tracked via the Priya Life Science China tracker
Sponsor
mingjun Zhong
Phase
Observational
Started
2016-01
Last updated
2026-03-13

Condition(s) studied

Mental DisordersHealthy Control

Investigational drug(s) / intervention(s)

Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids: Patients with mental disorders should take the appropriate medicine as prescribed by the doctor,and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.

Study summary

This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.

Eligibility

Sex
ALL
Min age
13 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age) * Course of disease: \<24 months * Priority is given to patients who have never taken medicine or duration of drug use \< 2 weeks * No nuclear magnetic contraindications. Exclusion Criteria: * Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence * Have a major physical disease or infectious disease * History of coma and serious neurological disease 4.MRI contraindications.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Second Xiangya hospital of central south univerity Changsha Hunan Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06580860 on ClinicalTrials.gov ↗ ← All trials in China